Amanda J Cross1, Johnson George1, Michael C Woodward2, David Ames3,4, Henry Brodaty5,6, Jenni Ilomäki1, Rohan A Elliott7,8. 1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia. 2. Medical and Cognitive Research Unit, Austin Health, Heidelberg, VIC, Australia. 3. National Ageing Research Institute, Parkville, VIC, Australia. 4. University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, VIC, Australia. 5. Dementia Collaborative Research Centre, School of Psychiatry, University of NSW, Sydney, NSW, Australia. 6. Centre for Healthy Brain Ageing, School of Psychiatry, University of NSW, Sydney, NSW, Australia. 7. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia. rohan.elliott@austin.org.au. 8. Pharmacy Department, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia. rohan.elliott@austin.org.au.
Abstract
BACKGROUND: There has been limited research into potentially inappropriate medication (PIM) use and anticholinergic burden in patients attending memory clinics. OBJECTIVES: The aim of this study was to explore the use of PIMs related to cognitive impairment (PIMcog), anticholinergic cognitive burden (ACB) and concomitant use of anticholinergic medications with cholinesterase inhibitors (ChEIs) in patients attending memory clinics. METHODS: Cross-sectional analysis of baseline data from the Prospective Research In MEmory clinics (PRIME) study was performed. Participants were community-dwelling patients who attended nine memory clinics and had a diagnosis of mild cognitive impairment or dementia. PIMcog were defined as any medication considered potentially inappropriate for patients with cognitive impairment according to the Beers or STOPP criteria. Clinically significant ACB was defined as total score of ≥3 on the ACB scale. RESULTS: A total of 964 patients, mean age 77.6 years, were included. PIMcog were used by 206 (21.4%) patients. Anticholinergics and sedatives were the most common PIMcog. PIMcog use was associated with higher number of medications (adjusted OR 1.26; 95% CI 1.19-1.33) and with not having completed secondary level education (adjusted OR 1.71; 95% CI 1.01-2.89). One hundred and thirteen (11.7%) patients had a clinically significant ACB score (≥3). ChEIs were used by 575 patients and 65 (11.3%) of these had an ACB score ≥3. There was no statistically significant difference in ChEI use between patients with and without an ACB score ≥3. CONCLUSION: PIMcog use, clinically significant anticholinergic burden, and concurrent use of anticholinergics with ChEIs were prevalent in patients attending memory clinics. Efforts are needed to improve prescribing for people with cognitive impairment.
BACKGROUND: There has been limited research into potentially inappropriate medication (PIM) use and anticholinergic burden in patients attending memory clinics. OBJECTIVES: The aim of this study was to explore the use of PIMs related to cognitive impairment (PIMcog), anticholinergic cognitive burden (ACB) and concomitant use of anticholinergic medications with cholinesterase inhibitors (ChEIs) in patients attending memory clinics. METHODS: Cross-sectional analysis of baseline data from the Prospective Research In MEmory clinics (PRIME) study was performed. Participants were community-dwelling patients who attended nine memory clinics and had a diagnosis of mild cognitive impairment or dementia. PIMcog were defined as any medication considered potentially inappropriate for patients with cognitive impairment according to the Beers or STOPP criteria. Clinically significant ACB was defined as total score of ≥3 on the ACB scale. RESULTS: A total of 964 patients, mean age 77.6 years, were included. PIMcog were used by 206 (21.4%) patients. Anticholinergics and sedatives were the most common PIMcog. PIMcog use was associated with higher number of medications (adjusted OR 1.26; 95% CI 1.19-1.33) and with not having completed secondary level education (adjusted OR 1.71; 95% CI 1.01-2.89). One hundred and thirteen (11.7%) patients had a clinically significant ACB score (≥3). ChEIs were used by 575 patients and 65 (11.3%) of these had an ACB score ≥3. There was no statistically significant difference in ChEI use between patients with and without an ACB score ≥3. CONCLUSION: PIMcog use, clinically significant anticholinergic burden, and concurrent use of anticholinergics with ChEIs were prevalent in patients attending memory clinics. Efforts are needed to improve prescribing for people with cognitive impairment.
Authors: Gobhathai Sittironnarit; David Ames; Ashley I Bush; Noel Faux; Leon Flicker; Jonathan Foster; Sarah Hilmer; Nicola T Lautenschlager; Paul Maruff; Colin L Masters; Ralph N Martins; Christopher Rowe; Cassandra Szoeke; Kathryn A Ellis Journal: Dement Geriatr Cogn Disord Date: 2011-03-09 Impact factor: 2.959
Authors: Johanna Jyrkkä; Hannes Enlund; Piia Lavikainen; Raimo Sulkava; Sirpa Hartikainen Journal: Pharmacoepidemiol Drug Saf Date: 2011-02-09 Impact factor: 2.890
Authors: T Sunderland; J L Hill; A M Mellow; B A Lawlor; J Gundersheimer; P A Newhouse; J H Grafman Journal: J Am Geriatr Soc Date: 1989-08 Impact factor: 5.562
Authors: Martin Taylor-Rowan; Olga Kraia; Christina Kolliopoulou; Anna H Noel-Storr; Ahmed A Alharthi; Amanda J Cross; Carrie Stewart; Phyo K Myint; Jenny McCleery; Terry J Quinn Journal: Cochrane Database Syst Rev Date: 2022-08-22
Authors: Sweilem B Al Rihani; Malavika Deodhar; Lucy I Darakjian; Pamela Dow; Matt K Smith; Ravil Bikmetov; Jacques Turgeon; Veronique Michaud Journal: Drugs Aging Date: 2021-11-09 Impact factor: 3.923
Authors: Martin Schulze Westhoff; Adrian Groh; Sebastian Schröder; Phileas Johannes Proskynitopoulos; Kirsten Jahn; Martin Klietz; Benjamin Krichevsky; Dirk O Stichtenoth; Felix Wedegärtner; Stefan Bleich; Helge Frieling; Johannes Heck Journal: J Neural Transm (Vienna) Date: 2022-09-02 Impact factor: 3.850